Expression of Drug-Resistant Factor Genes in Hepatocellular Carcinoma Patients Undergoing Chemotherapy with Platinum Complex by Arterial Infusion
Open Access
- 9 September 2010
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 2 (3), 300-312
- https://doi.org/10.3390/pharmaceutics2030300
Abstract
This study investigated gene expression of drug resistance factors in biopsy tissue samples from hepatocellular carcinoma (HCC) patients undergoing chemotherapy by platinum complex. Liver biopsy was performed to collect tissue from the tumor site (T) and the non-tumor site (NT) prior to the start of treatment. For drug-resistant factors, drug excretion transporters cMOAT and MDR-1, intracellular metal binding protein MT2, DNA repair enzyme ERCC-l and inter-nucleic cell transport protein MVP, were investigated. The comparison of the expression between T and NT indicated a significant decrease of MT2 and MDR-1 in T while a significant increase in ERCC-1 was noted in T. Further, expression was compared between the response cases and non-response cases using the ratios of expression in T to those in NT. The response rate was significantly low in the high expression group when the cutoff value of cMOAT and MT2 was set at 1.5 and 1.0, respectively. Furthermore, when the patients were classified into A group (cMOAT ≧ 1.5 or MT2 ≧ 1.0) and B group (cMOAT < 1.5 and MT2 < 1.0), the response rate of A group was significantly lower than B group when we combined the cutoff values of cMOAT and MT2. It is considered possible to estimate the therapeutic effect of platinum complex at a high probability by combining the expression condition of these two genes.This publication has 47 references indexed in Scilit:
- Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family)The Journal of pharmacology and experimental therapeutics, 2006
- Hepatobiliary transporter expression in human hepatocellular carcinomaLiver International, 2005
- Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agentsThe Esophagus, 2004
- Upregulation of DNA repair genes in active cirrhosis associated with hepatocellular carcinomaFEBS Letters, 2004
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- The Copper Export Pump ATP7B Modulates the Cellular Pharmacology of Carboplatin in Ovarian Carcinoma CellsMolecular Pharmacology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- In vivo Cisplatin Resistance Depending upon Canalicular Multispecific Organic Anion Transporter (cMOAT)Japanese Journal of Cancer Research, 1999
- Overexpression of P-glycoprotein in adenomatous hyperplasia of human liver with cirrhosisJournal of Hepatology, 1995
- Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product p-glycoprotein in primary liver carcinomaCancer, 1994